Genome Editing: Technologies and Global Markets

Report Scope

This report analyzes the market for genome editing technologies, applications and end users, offering insights into the market and technological trends. The study focuses on technologies such as CRISPR-Cas, transcription activator-like effector nucleases (TALEN) and zinc finger nucleases (ZFN), assessing their adoption in biopharmaceutical, agricultural biotech and research sectors. The market is segmented by applications into drug development, plant breeding, diagnostics and clinical therapy.

The report provides an analysis covering the regions of North America, Europe, Asia-Pacific and the Rest of the World (RoW), which includes Latin America, the Middle East and Africa. It evaluates the drivers, restraints, opportunities and challenges affecting the market and vendor landscape. It discusses clinical trials, patents and emerging technologies related to the market and looks at ESG-related developments.

The study offers an analysis of the competitive landscape, which ranks the top companies in the global market for genome editing. It also has a section with company profiles covering details of the market leaders. For market estimates, data has been provided for 2022 and 2023 as the historic years, 2024 as the base year, and forecasts for 2025 to 2030.

Report Includes

• 52 data tables and 58 additional tables
• A review of the global market for genome editing technologies
• Analyses of the global market trends, with market revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
• Evaluation and forecast of the genome editing market, and a corresponding market share analysis by product, application, end user and geographic region
• In-depth facts and figures concerning market drivers and deterrents, and other macroeconomic forces influencing the genome editing market
• A look at the use of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, and how it has fueled the growth of the genome editing industry
• An evaluation of the recent technological breakthroughs and issues, market regulations, and the current status of the intellectual property rights of the CRISPR-Cas9 genome editing technology
• Review of patent trends and research publications in the global genome editing industry
• Insight into the industry structure, competitive landscape, R&D activity, growth strategies and ESG trends
• Identification of the companies best positioned to meet market demand due to their proprietary technologies, mergers and acquisitions, joint ventures and other strategic alliances
• Profiles of the leading companies, including Merck KGaA, Thermo Fisher Scientific, Beam Therapeutics, CRISPR Therapeutics, and Cellectis S.A.
  
  Companies Mentioned
  
  Agilent Technologies Inc.
  Beam Therapeutics
  Caribou Biosciences Inc.
  Cellectis S.A.
  Crispr Therapeutics
  Editas Medicine
  Genscript
  Intellia Therapeutics Inc.
  Merck Kgaa
  Origene Technologies Inc.
  Precision Biosciences
  Sangamo Therapeutics
  Takara Bio Inc.
  Thermo Fisher Scientific Inc.
  Verve Therapeutics Inc.